Brii Biosciences
PublicBrii Biosciences is now publicly traded
The data on this page reflects Brii Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 13, 2021
Last Round
Series C
Mar 23, 2021
Total Funding Raised
$731.93M
Company Overview
Brii Biosciences is a biotechnology company dedicated to advancing therapies for infectious diseases and CNS disorders, with a pipeline of over 10 product candidates targeting significant public health challenges.
Sector
Biotech
AI Layer
Non-AI
Keywords
Brii Biosciences Comparables
Compare Brii Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai Ark Biopharmaceutical Co., Ltd. | 64% | |
| EIT Pharma | 48% | |
| Trellis Bioscience | 46% |
Brii Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jul 13, 2021 | ||||
| Series C | Mar 23, 2021 | ||||
| Series B | Dec 27, 2019 | ||||
| Series A | Jun 22, 2018 |
Brii Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series A, IPO, Series B |
| Lake Bleu Capital | Series C |
| OppenheimerFunds | Series C |
| RBC Global Asset Management (Asia) Limited | IPO |
| Blue Pool Capital | Series A, Series B |
| The Valliance Fund | IPO |
| China International Capital Corporation | IPO |
Brii Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access